AngioDynamics, Inc. (ANGO) Balance Sheet

The steady decline in total assets and equity, despite a recent uptick in cash, indicates the company is liquidating or depreciating assets to fund operations. This trajectory is unsustainable without a clear path to profitability, as the shrinking asset base limits future operational capacity and financial flexibility.

The company's liquidity appears adequate for the near term, with a current ratio consistently above 2.0. However, the volatility in cash balances, which fell from $78.5M in 2024Q3 to $53.9M in 2026Q4, indicates that cash generation is not yet stable and is heavily influenced by working capital swings, warranting close monitoring.

The persistent and deepening negative retained earnings figure is a stark indicator of the company's inability to generate cumulative profits. This structural equity weakness means the balance sheet is fundamentally reliant on external capital or asset liquidation to sustain operations, a position that becomes increasingly precarious without a turnaround in profitability.

The high proportion of goodwill relative to a shrinking asset base suggests that a substantial portion of the company's value is tied to past acquisitions rather than tangible, productive assets. This concentration increases the risk of a material write-down if future cash flows from acquired businesses fail to meet expectations, which would further erode the already weakened equity position.